Latest Articles

Publication Date
Computational image and molecular analysis reveal unique prognostic features of immune architecture in African Versus European American women with endometrial cancer - Nature

Computational image and molecular analysis reveal unique prognostic features of immune architecture in African Versus European American women with endometrial cancer Nature

Published: June 23, 2025, 7:30 a.m.
Integrating Deep Learning and Clinical Characteristics for Early Prediction of Endometrial Cancer Using Multimodal Ultrasound Imaging: A Multicenter Study - Frontiers

Integrating Deep Learning and Clinical Characteristics for Early Prediction of Endometrial Cancer Using Multimodal Ultrasound Imaging: A Multicenter Study Frontiers

Published: June 19, 2025, 2:09 p.m.
1st patient dosed in trial of Enhertu for HER2 endometrial cancer - Rare Cancer News

1st patient dosed in trial of Enhertu for HER2 endometrial cancer Rare Cancer News

Published: June 18, 2025, 4:01 p.m.
Endometrial Cancer Treatment Market Overview With Key USA Updates and Global Outlook - openPR.com

Endometrial Cancer Treatment Market Overview With Key USA Updates and Global Outlook openPR.com

Published: June 18, 2025, 7:49 a.m.
Hera Biotech Acquires Point-of-Care Cervical Cancer Diagnostic HeraFem - Femtech Insider

Hera Biotech Acquires Point-of-Care Cervical Cancer Diagnostic HeraFem Femtech Insider

Published: June 18, 2025, 6:38 a.m.
Womb cancer 'really hitting the Pacific and Māori communities', NZ biologist says - RNZ

Womb cancer 'really hitting the Pacific and Māori communities', NZ biologist says RNZ

Published: June 18, 2025, 2:03 a.m.
Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC - CancerNetwork

Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC CancerNetwork

Published: June 17, 2025, 6:09 p.m.
Galesburg family launches cancer-awareness website - WQAD

Galesburg family launches cancer-awareness website WQAD

Published: June 16, 2025, 3:18 p.m.
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - MSN

AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer MSN

Published: June 16, 2025, 11:46 a.m.
Cartherics COO Dr Ian Nisbet on the promise of CAR-NK cells for cancer and endometriosis at BIO 2025 - BioSpectrum Asia

Cartherics COO Dr Ian Nisbet on the promise of CAR-NK cells for cancer and endometriosis at BIO 2025 BioSpectrum Asia

Published: June 16, 2025, 11:42 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!